Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

Secondary pulmonary hypertension

Postcapillary Blood Gas Analysis in Wedge Position (Wedge-BGA) The Role of Endothelin in Pulmonary Hypertension Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure Sildenafil in US Heart Failure Patients (SilHF-US) Sildenafil Versus Placebo in Chronic Heart Failure Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension? Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD) Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension Bosentan for Severe Mitral Valve Dysfunction